Häufige Suchbegriffe
Suchergebnisse
7 Ergebnisse-
Vielfalt bei CSL
Werte - Patientenfokus, Spitzenleistungen, Innovation, Integrität und Zusammenarbeit. und zu motivieren; - Kreativität und Innovation zu fördern; - die Qualität unserer
https://www.cslbehring.de/-/media/cslb-germany/documents/diversity_onesheet_high_german_final.pdf -
CSL Behring Fact Sheet - März 2019
Die Muttergesellschaft CSL Limited (AXS: CSL, USOTC: CSLLY) hat ihren Hauptsitz in Melbourne, Australien. . INNOVATION Das Bekenntnis von CSL Behring zur Innovation spiegelt sich
https://www.cslbehring.de/-/media/shared/documents/factsheet85x11ger.pdf -
R&D Investor Briefing 2016
New Indications Anticipating Disruptive Innovation Immunoglobulins 19 Immunoglobulin Global Ig Specialty Coag Deliver Innovation Demonstrate Leadership Drive Growth
https://www.cslbehring.de/-/media/shared/documents/7/rd-investor-briefing-2016.pdf -
Microsoft Word - Climate Change Statement
international approaches, and are designed to encourage investment and innovation in greenhouse gas mitigating technologies, while limiting adverse impacts on national economies.
https://www.cslbehring.de/-/media/csl/documents/csl-governance-docs/climate-change-statement.pdf -
R&D Investor Briefing 2014
Scientific and product innovation . Patient benefit Innovation to Drive Growth Patient benefit primary driver of innovation . Albumin fusion technology . rIX-FP, rVIIa-FP, rvWF-FP
https://www.cslbehring.de/-/media/shared/documents/7/rd-investor-briefing-2014.pdf -
R&D Investor Briefing 2015
Supporting and enhancing plasma products and developing novel recombinant portfolio with focus on: o Scientific and product innovation o Patient benefit . Key Focus o IDELVION TM
https://www.cslbehring.de/-/media/shared/documents/7/rd-investor-briefing-2015.pdf -
PowerPoint Presentation
Supporting and enhancing plasma products and developing novel recombinant portfolio with focus on: . Scientific and product innovation . Patient benefit . Key Focus: . IDELVION ®
https://www.cslbehring.de/-/media/shared/documents/7/rd-investor-briefing-2018.pdf